Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Genetics

Open Access

Epigenetic modifications of caveolae associated proteins in health and disease

BMC Genetics201516:71

https://doi.org/10.1186/s12863-015-0231-y

Received: 4 March 2015

Accepted: 15 June 2015

Published: 26 June 2015

Abstract

Caveolae are small, “omega-shaped” invaginations at the plasma membrane of the cell which are involved in a variety of processes including cholesterol transport, potocytosis and cell signalling. Within caveolae there are caveolae-associated proteins, and changes in expression of these molecules have been described to play a role in the pathophysiology of various diseases including cancer and cardiovascular disease. Evidence is beginning to accumulate that epigenetic processes may regulate the expression of these caveolae related genes, and hence contribute to disease progression. Here, we summarize the current knowledge of the role of epigenetic modification in regulating the expression of these caveolae related genes and how this relates to changes in cellular physiology and in health and disease.

Keywords

CaveolaeEpigeneticmicro-RNAPromoter methylationHistone acetylationPTRFCaveolin-1Caveolin-25-AZATrichostatin-A

Introduction

Caveolae are small specialized “cave-like” microdomains at the plasma membrane that function as trafficking vesicles and are involved in organization of signal transduction. Caveolae are present in most tissues and are particularly abundant in cardiac, continuous endothelial and epithelial cells, as well as fat cells [13]. Within caveolae are caveolae associated proteins; caveolin-1 (CAV1) [4], caveolin-2 (CAV2) [5], caveolin-3 (CAV3) [6], Cavin-1 (also know as polymerase-1 and transcript release factor) (PTRF) [7], Cavin-2 [8], Cavin-3 [9] and Cavin-4 [10], which are important for the formation and maintenance of the caveolar structure.

CAV1 is a 22 kDa protein which is the principal substrate of src kinase [11] and appears as a filament-like structure at the plasma membrane [12]. CAV1 is expressed in a wide range of tissues with the highest expression in smooth muscle cells, adipocytes, fibroblasts and endothelial cells [13]. CAV1 plays an important role in the formation of caveolae; if cells lack CAV1, no caveolae are observed [14] while, restoration of CAV1 expression results in the de novo formation of caveolae [15, 14]. CAV1 knock out mice demonstrate a variety of physiological defects including reduced renal calcium reabsorption and vascular and metabolic abnormalities [1618]. CAV1 is also reported to be involved in diseases such as cancer, cardiovascular disease and diabetes (for review see [19]).

CAV2 is a 20 kDA protein found abundantly in white adipose tissue [5]. Expression of CAV2 is independent of caveolae formation, however, co-expression of CAV2 with CAV1 results in more abundant invaginations and more uniform caveolae formation [20, 21]. Thus while CAV2 may not be essential, it plays a supporting role in modulating the biogenesis of caveolae. CAV2 is expressed concurrently with CAV1 and can undergo hetro-oligomerization with CAV1 [22]. In addition, CAV2 has been shown to interact with CAV3 in cardiac muscle cells [23]. CAV2 knock out mice have normal distribution of caveolae but display a variety of lung disorders [21].

CAV3 has a molecular weight of 18–20 kDA and is 85 % similar to CAV1 [6]. It is predominantly expressed in muscle cells [6]. CAV3 co-immunoprecipitates with dystrophin, suggesting that dystrophin and CAV3 can exist as a discrete complex [24]. In embryonic fibroblasts derived from caveolae-null mice, restoration of CAV3 successfully restores the formation of caveolae [25]. CAV3 knock out mice show a loss of caveolae at the sarcolemma (but not endothelial cells), exclusion of dystrophin-glycoprotein complexes from the lipid rafts, abnormalities of the T-tubule system, insulin resistance and instability of the insulin receptor in skeletal muscle [26, 27]. Similarly, analysis of cardiac muscle from CAV1 knock out mice demonstrates a loss of caveolae in the cardiac endothelial cells but not cardiac myocytes, however the opposite observation was seen in CAV3 knock out mice [28]. Only in CAV1 CAV3 double knock out mice were caveolae completely abolished in both cell types [28]. This suggests that CAV3 can compensate for CAV1 allowing caveolae formation in cardiac myocytes, providing some functional redundancy [28].

PTRF was cloned in 1998 and was first described to be involved in RNA transcription machinery [29, 30]. PTRF is a resident protein in caveolae [31] and is widely expressed in a range of tissues, with highest expression in adipocytes, cardiac and skeletal muscles and osteoblasts [32]. The functional role of PTRF in caveolae formation has only recently been described. Loss of PTRF is accompanied by reduced numbers of caveolae [33, 34]. Re-expression of PTRF in cell lines that have reduced or lack PTRF results in caveolae formation [35, 7]. PTRF knock out mice lack caveolae and demonstrate glucose intolerance and disorders of the lungs and cardiovascular system [34, 3639].

Structurally, Cavin-2 is ~ 20 % similar to PTRF [40]. Although down-regulation of Cavin-2 in turn causes reduced PTRF and CAV1 expression (hence reduced caveolae number), suggesting the interdependency between these 3 molecules [8], the expression of Cavin-2 alone does not alter the number of caveolae [40, 41]. However, the expression of Cavin-2 induces tube-like morphological changes to caveolae [40]. Cavin-3 is reported to be associated with CAV1 during caveolae budding [9]. The process of caveolae budding and trafficking of caveolae-associated vesicles along the microtubules is greatly impaired in the absence of Cavin-3, suggesting a role of Cavin-3 in intracellular transport mechanisms [9]. Cavin-4 is only present in muscle cells and is a cytosolic protein that is able to interact with Cavin-2. Cavin-4 has been demonstrated to be important in cardiac dysfunction where Cavin-4 is able to modulate the Rho/ROCK pathway that is important for cardiac muscle biogenesis [42].

Changes in the expression of the caveolae related proteins are associated with disease. For example, expression of CAV1, CAV2 and PTRF is dysregulated in prostate and breast cancer [33, 43]. Furthermore, other health issues such as cardiovascular disease, inflammation and abnormal insulin signaling are associated with changes in these proteins [44, 39]. However, what causes the change in expression of these caveolae related molecules is unknown. Potentially, these changes may be related to epigenetic or micro-RNA (miRNA) mechanisms that act upstream of the genes. This review brings together the current evidence for epigenetic regulation of these genes and thus, presence of caveolae. As there are limited data, or no evidence, published on CAV3, Cavin-2, Cavin-3 and Cavin-4, this review will focus on CAV1, CAV2 and PTRF.

Review

Evidence for epigenetic changes related to CAV1, CAV2 and PTRF

Epigenetics involves the study of the changes in gene expression that are independent of any changes in DNA sequences. There are two main mechanisms under the umbrella of epigenetics; DNA methylation, which involves the methylation of the promoter region of the gene and histone deacetylation which involves structural changes of the chromatin. Importantly epigenetic changes can be reversed with the use of chemical agents [45].

DNA promoter hypermethylation involves the modification of cytosine residues in the CpG dinucleotides to form 5-methylcytosine through covalent addition of a methyl group by the enzyme, DNA methyltransferase. In the mammalian genome, CpG dinucleotides are unevenly distributed to form short sequences that have high densities of CpG dinucleotides known as CpG islands (CpGi) [46], within the promoter region of the genome. Gene promoters which have their CpGi methylated are transcriptionally inactive as the methyl groups block the promoter region from being accessed by transcriptional elements [45]. Chemical agents such as 5-AZA-2′-deoxycytidine (5-AZA) have been reported to reverse DNA promoter hypermethylation [4749].

More recent studies suggest that methylation can also occur in non-CpGi rich areas in the promoter region to silence gene expression. These regions have a lesser density of CpGi and are normally situated around 2 kb from the regular CpGi rich regions, and have been named CpGi shores [50, 51]. Hypermethylation at the CpGi shore appears to have a critical role in regulating gene expression [50]

Allfrey et al. [52] described that for gene expression to take place, the ε-amino group in the lysine residue of the histone cores must be acetylated by histone acetyltransferases (HATs). Histone deacetylases (HDACs) cancel the effect of HATs by removing acetyl groups from the lysine residue in histone cores. The removal of acetyl groups by HDACs restores the positive charges on lysine residues. This causes the histone tails to coil tightly to the DNA leading to transcriptional inactivation as the transcriptional machinery is unable to access the DNA [52, 53]. The use of Trichostatin-A (TSA), a microbial metabolite capable of inhibiting HDACs, was first described in 1995 and has been used to re-express genes which are inactivated by histone deacetylation [54]. Gene transcription is restored when lysine residues in the histone tails are acetylated through inactivation of HDACs by TSA [54].

To date, most of the reports of epigenetic effects on CAV1 are related to DNA methylation and in the context of cancer (Table 1). It is suggested that the 5′ promoter of CAV1 is methylated in human breast cancer cell lines, MDA-MB-231, MCF7 and T-47D but not in normal human mammary epithelial cells [55, 43]. Studies of clinical tissues have shown that breast cancer tissues have hypermethylation of the CAV1 promoter accompanied by down-regulation of CAV1 expression when compared to adjacent normal breast tissues [56, 57]. Furthermore, CAV1 promoter hypermethylation is significantly associated with the histopathological grade of the tumor [56].
Table 1

Involvement of CAV1 epigenetic modification in cancers

Cancer types

Promoter hypermethylation

Histone modification

CAV1 expression

Changes in physiology and pathophysiology

Breast

[55]

[59]

Down-regulated

Decreased migration after 5-AZA and TSA treatment [59]

[57]

[43]

[56]

[59]

[58]

Prostate

[62]

 

Down-regulated

Not described

 

[64]

   
 

[63]

   

Bladder

[68]

 

Down-regulated

Not described

Ovarian

[71]

[71]

Down-regulated

Over-expression of CAV1, reduced colony formation and increased apoptosis in ovarian cancer cell line [71]

Lung

[70]

 

Down-regulated

Over-expression of CAV1, reduced colony formation in lung cancer cell line [70]

Colorectal

[72]

 

Down-regulated

Not described

[73]

[74]

Liver

[75]

 

Down-regulated

Not described

[77]

Nodal metastasis has been reported to be associated with CAV1 hypermethylation [58]. It has been suggested that inactivation of CAV1 through hypermethylation drives the spread of breast cancer to the lymph nodes [58]. Treatment of breast cancer cell lines with 5-AZA successfully increases both CAV1 mRNA and protein [43, 59]. However, in a subtype of breast cancer, inflammatory breast cancer (IBC), CAV1 is reported to be hypomethylated resulting in overexpression of CAV1 [60]. Therefore it may suggest that different breast cancer subtypes may have different changes in epigenetic regulation of CAV1.

Recent evidence suggests that CpGi shores are involved in regulation of CAV1 expression. Treatment with a DNA methyltransferase inhibitor induces expression of CAV1 through demethylation of CpGi shores in breast cancer cell lines that have low CAV1 expression (even though the CpGi rich promoters are hypermethylated) [61]. CpGi shores are reported to be hypermethylated in less aggressive breast cancer cells whereas hypomethylation of CpGi shores is observed in highly aggressive breast cancer cells [61].

In prostate cancer CAV1 is down-regulated and this is accompanied by promoter hypermethylation of CpGi sites at the 5′ promoter region of CAV1 [62, 63]. Bisulfite sequencing suggests promoter hypermethylation may be a mechanism for down-regulation of CAV1 gene expression [64]. However, loss of CAV1 expression was observed in androgen dependent LNCaP cells while increased expression occurred in PC3 cells and tissues from advanced cancer [33]. Thus, expression of CAV1 may be lost in the early stages of prostate cancer and promote cancer cell proliferation and survival, but up-regulated at late stages of prostate cancer to favor metastasis, inhibit apoptosis and promote multi-drug resistance [65]. A possible explanation for the conditional role of CAV1 as both tumor promoter and suppressor is the interaction of CAV1 with other effector molecules that may directly or indirectly interact with or affect CAV1’s function [65]. Possible examples are Mgat5 and galectin-3. In early stages of prostate cancer, the expression of CAV1 is lost and the expression of Mgat5 and galectin-3 is at low levels. However, in later stages of prostate cancer, expression and formation of Mgat5/galectin-3 lattices may stimulate and elevate the expression of CAV1 through phosphorylation, resulting in up-regulated CAV1 expression in advanced prostate tumours [6567].

Promoter methylation is also seen in a variety of other cancers and appears to be cell specific in a given organ (Table 1). For example, CAV1 promoter methylation is seen in undifferentiated small cell and squamous cell carcinoma but not in transitional cell [68] or primary adenocarcinomas and signet ring cell carcinomas of the bladder [69]. Similar cell specificity is seen in lung cancers [70].

Treatment with 5-AZA has been shown to restore CAV1 expression in some cancers confirming hypermethylation. CAV1 expression is down-regulated in ovarian cancer cell lines but expression can be restored by treating the cells with 5-AZA [71]. CAV1 promoter hypermethylation has also been reported in sporadic colorectal cancer [72] and re-expression of CAV1 was observed in colon cancer cell lines after 5-AZA treatment [73, 74].

Promoter hypermethylation of CAV1 is also seen in hepatocellular carcinoma (HCC) cell lines [75] and HCC tissues and is accompanied by reduced expression of CAV1 [75]. Further, 5-AZA treatment causes up-regulated CAV1 expression in hepatoma cells [75]. One of the risk factors for hepatocellular carcinoma (HCC) is exposure to Hepatitis B Virus (HBV) and in particular to HBV’s X protein. This protein is able to promote tumorigenesis through activation of signaling pathways, growth factors and oncogenes. Furthermore, HBV’s X protein inactivates negative growth regulators such as p53 to favor metastasis [76, 77]. Interestingly, HCC samples that are infected with HBV show significant suppression of CAV1 expression through hypermethylation of CAV1’s promoter [77], due to the hypermethylation effect of HBV’s X protein on CAV1’s promoter (Fig. 1) [77].
Fig. 1

Effect of HBV’s X protein on CAV1 expression. HCC samples infected with HBV demonstrate decreased CAV1 expression. This effect is due to the promoter hypermethylation of CAV1 by HBV’s X protein, causing transcriptional silencing of CAV1

Other than promoter hypermethylation, histone modification has also been reported as a mechanism to silence CAV1 expression. In ovarian cancer cell lines, treatment with TSA up-regulates CAV1 [71] and in breast cancer cell lines, TSA treatment results in a 35 fold increase in CAV1 expression [59].

Estrogen receptors alpha (ERα) and beta (ERβ) are expressed in neuronal cells [78, 79]. Ectopic expression of ERα in SK-N-MC neuronal cells leads to epigenetic silencing of CAV1 (and down-regulation of CAV1) while treatment with 5-AZA and TSA results in partial restoration of CAV1 expression. However, when ERβ is co-expressed with ERα in SK-N-MC cells, the effect on CAV1 is abolished, suggesting ERβ counteracts the effect of ERα on CAV1 down-regulation through an epigenetic pathway (Fig. 2) [80]. However, the exact molecular mechanism is not well understood and this observation may be due to a direct ERα targeting effect or indirect silencing of CAV1 through ectopic expression of ERα. In neuronal cells that over-express ERα, CAV2 expression is also down-regulated. 5-AZA treatment results in re-expression of CAV2, but TSA treatment has no effect [80]. This suggests that ERα is able to silence CAV2 through DNA promoter methylation but not histone modification, suggesting another level of regulation.
Fig. 2

The mechanism of action of ER isoforms on CAV1 expression. Over-expression of ERα leads to down-regulation of CAV1 expression through epigenetic mechanisms. However, the co-expression of ERβ inhibits the effect of ERα, resulting in removal of the transcriptional suppression activity of ERα

To date, there are limited data describing the epigenetic regulation of PTRF. PTRF is down-regulated in breast cancer cell lines and tissues and this is related to promoter hypermethylation since PTRF was successfully restored through 5-AZA treatment [43].

Summary of epigenetics and caveolae related genes

There is growing evidence of a role of epigenetic mechanisms in regulating CAV1, particularly in cancer (Table 1). These effects appear to be cell type specific and different epigenetic mechanisms may be involved in cells from different tissues. There is still limited knowledge on how epigenetics may regulate other caveolae related genes (CAV2, CAV3 and PTRF).

Evidence of microRNA regulation of CAV1, CAV2 and PTRF

MicroRNAs (miRNAs) are able to regulate target transcription and hence protein expression through binding to the 3′-untranslated region of the matching target mRNA [81, 82]. These small nucleotides have been reported to be widely involved in physiological and pathophysiological processes such as apoptosis [83], cellular differentiation [84] and oncogenesis [85].

miRNAs have been shown to act as both tumor promoters and suppressors. Evidence suggests that miRNA-133a may act as an upstream regulator of CAV1 expression in head and neck squamous cell carcinoma (HNCC) as the expression of miRNA-133a is down-regulated while CAV1 is up-regulated in HNCC [86]. Luciferase reporter assays showed that miRNA-133a interacts directly with CAV1 mRNA and transfection with a mirRNA-133a mimic results in down-regulated CAV1 expression [86].

In vivo, a diet high in potassium results in increased expression of renal outer medullary potassium (ROMK) channels, an effect thought to be mediated by up-regulation of miRNA-802 [87]. The 3′-untranslated region (UTR) of CAV1 contains sequences that allow direct interaction with miRNA-802. CAV1 inhibits ROMK channel activity by interacting with the N-terminus of ROMK channels [87]. When potassium increases, up-regulation of miRNA-802 occurs which down-regulates CAV1’s expression by binding to the 3′UTR of CAV1. As CAV1 is able to interact with the N-terminus of the ROMK channels (to down-regulate its expression) down-regulation of CAV1 by miRNA-802 results in up-regulation of the ROMK channels (Fig. 3) [87].
Fig. 3

The role of dietary potassium in regulating miRNA-802 and CAV1 expression in the kidney. A diet high in potassium results in up-regulation of miRNA-802 which down-regulates CAV1’s expression by binding to 3′UTR of CAV1. Interaction of CAV1 with the N-terminus of the ROMK channels down-regulates these ion channels in the distal nephron, down-regulation of CAV1 results in up-regulation of the ROMK channels

In obese mice, miRNA-103 and 107 are up-regulated and may contribute to impaired glucose homeostasis [88]. Knocking down both miRNAs results in an improved response to insulin and glucose homeostasis [88]. CAV1 regulates insulin signaling [89] and CAV1 is reported to be a target for both miRNA-103 and 107 [88]. Knocking down both miRNAs results in up-regulation of CAV1 [88] and a stabilization of insulin receptors and a responsive insulin signaling mechanism [88]. The findings suggest the potential use of miRNA-103 and 107 as therapeutic targets in treating diabetes and obesity.

CAV1 has been shown to be a direct target for miRNA-199a-5p in the context of tissue fibrosis of several organs (liver, kidney, lungs) [90]. Up-regulation of miRNA-199a-5p in these tissues results in down-regulation of CAV1 [90]. Interestingly, TGF-β, a factor involved in fibrosis, induces the expression of miRNA-199a-5p, which in turn causes the down-regulation of CAV1 in these tissues [90]. In porcine adipocytes, there is a high expression of miRNA-199a-5p [91]. Over-expression of miRNA-199a-5p increases proliferation of pre-adipocytes and inhibits the deposition of lipid in adipocytes [91]. CAV1 has been shown to be involved in lipogenesis [92, 17] and potentially miRNA-199a-5p may play a role in controlling proliferation of adipocytes, partly through regulating the expression of CAV1.

In porcine kidney epithelial (PK15) cells, miRNA-124 has been shown to directly interact with CAV1. In these cells over-expression of miRNA-124 reduces CAV1 expression at both mRNA and protein levels, thus reducing caveolae density and is associated with reduction in pathogen uptake [93]. Therefore, expression of miRNA-124 is proposed to be an important event that inhibits invasion of pathogens in the kidney through down-regulation of CAV1, and hence caveolae [93].

Docosahexaenoic acid (DHA) has been reported to modulate the transcriptome of miRNAs in lipid metabolism [94]. Exposure to DHA significantly increases the expression of miRNA-192 in enterocytes and CAV1 is predicted to be a target for miRNA-192. Over-expression of miRNA-192, results in reduced CAV1 expression [94]. However, the biological significance of this relationship is not yet known.

Expression of miRNA-199a-3p has been reported to be critical in promoting proliferation and survival of endothelial and breast cancer cells. CAV2 has been shown to be a target of miRNA-199a-3p [95] with over-expression of CAV2 inhibiting the effect exerted by miRNA-199a-3p in promoting proliferation, survival and sensitivity of cancer cells to anticancer drugs [95]. The interaction between miRNA-199a-3p and CAV2 may provide an interesting target for intervention in cancer.

Loss of miRNA-218 and up-regulation of CAV2 have been observed in renal cell carcinoma (RCC) [96]. Over-expression of miRNA-218 and knocking down CAV2 significantly inhibits cellular proliferation, migration and invasion of RCC [96]. Gene expression studies reveal CAV2 to be regulated by miRNA-218. It has been suggested that miRNA-218 acts as tumor suppressor by regulating CAV2, possibly through the focal adhesion pathway in RCC [96].

Interestingly, it has been shown that intestinal Salmonella infection is associated with miRNA-29a and CAV2. CAV2 has been shown to be a direct target for miRNA-29a [97]. Infection with Salmonella causes up-regulation of miRNA-29a, which in turn results in down-regulation of CAV2 and this is associated with reduced proliferation of intestinal epithelial cells and increased bacterial uptake in the intestinal epithelial cells [97]. Further, over-expression of CAV2 or inhibition of miRNA-29a leads to activation of CDC24 (an important molecule that promotes the uptake of Salmonella into cells), suggesting a possible mechanistic pathway for Salmonella infection [97].

To date, there are no findings that describe a relationship between miRNA and PTRF. However, a recent study suggests that expression of PTRF may modulate the content of miRNA in extracellular vesicles secreted from prostate cancer cells [98].

Summary of miRNA and caveolae related genes

The discovery and identification of miRNAs is beginning to provide understanding of the upstream regulatory mechanisms that regulate the expression of caveolae related genes. Some evidence is available for a relationship between miRNA and CAV1 and CAV2 (Table 2). However, the lack of the knowledge between miRNA and other caveolae related genes warrants further investigation.
Table 2

Relationship between miRNA and CAV1 and CAV2 in health and disease

miRNA

Target caveolae related gene

Changes observed and involvement in health and diseases

miRNA-133a

CAV1

miRNA-133a is up-regulated in head and neck squamous cell carcinoma and down-regulates CAV1 [86]

miRNA-802

CAV1

miRNA-802 is increased and up-regulates potassium channel expression in kidney by down-regulating CAV1 [87]

miRNA-103

CAV1

miRNA-103 is up-regulated in obese animals and associated with impaired glucose homeostasis by down-regulating CAV1 [88]

miRNA-107

CAV1

miRNA-107 is up-regulated in obese animals and associated with impaired glucose homeostasis down-regulating CAV1 [88]

miRNA-199a-5p

CAV1

miRNA-199a-5p is over-expressed in tissue fibrosis and pre-adipocytes, affects tissue fibrosis and proliferation of pre-adipocytes [91, 90]

miRNA-124

CAV1

miRNA-124 down-regulates CAV1 and caveolae to prevent uptake of pathogens in kidney cells [93]

miRNA-192

CAV1

Exposure to DHA up-regulates miRNA-192 and down-regulates CAV1 [94]

miRNA-199a-3p

CAV2

miRNA-199a-3p is up-regulated in breast cancer and down-regulates CAV2 [95]

miRNA-218

CAV2

miRNA-128 is down-regulated in renal cell carcinoma and up-regulates CAV2 [96]

miRNA-29a

CAV2

miRNA-29a is up-regulated following Salmonella infection and down-regulates CAV2 [97]

Perspective

Evidence suggests that environment and lifestyle factors may alter the epigenetic and miRNA profile in humans and contribute to disease [99]. As discussed above, caveolae related genes have been shown to play a role in the pathophysiology of various disease states, especially cancer. Although there is no evidence yet available that environmental changes or diets affect caveolae related genes epigenetically, growing evidence suggests that diet could affect the expression of miRNAs which will then affect the expression of caveolae related genes. Furthermore, it would be interesting to investigate the downstream effects of epigenetic changes to cellular physiology and pathophysiology. Currently, limited evidence is available on this aspect as most of the studies focus on the interaction of epigenetic changes to a particular caveolae related gene but not the downstream effects (eg: changes in cellular signaling mechanisms).

The involvement of mutations of the caveolae related genes may also contribute to changes in cellular physiology and pathophysiology. Mutations of CAV1 and PTRF have been shown to be involved in congenital lipodystrophy [100, 101]. As yet there is no evidence available that epigenetic changes in expression of these genes causes lipodystrophic effects, this may suggest that epigenetic changes and mutations of caveolae related genes may predispose to different disease conditions through these two different pathways. Currently there are limited data concerning genetic mutations of CAV2 or other caveolae associated genes.

Potentially, changes in the epigenetic status of caveolae related genes could be developed as a biomarker for diseases, in particular cancers. This could have several advantages. Firstly, DNA is more stable than RNA and secondly there are difficulties in differentiating between RNA from normal and tumor cells, meaning that there are advantages in using DNA as a biomarker over RNA [102, 103]. Furthermore, DNA promoter hypermethylation occurs uniquely in the CpG rich area in the promoter whereas genetic mutations can occur randomly within the coding and non-coding region, and promoter hypermethylation is an all-or-none event that can be detected easily with a single pair of primers. Lastly, minimally invasive methods can be used to collect samples (for example urine and plasma) that can then be used to detect epigenetic changes [104, 103]. Potentially, caveolae related genes that are silenced through epigenetic mechanisms may be a useful biomarker for diagnostic purposes in the future.

miRNA has been reported to be dysregulated in a variety of disease conditions. Even though the use of siRNA as a therapeutic target is being clinically trialed, the use of siRNA as a therapeutic target still poses some challenges. The high specificity, low toxicity, unique biogenesis and mechanism of action and the multiple targeting ability of miRNA provide advantages over siRNA. With the recognition of miRNA-caveolae related gene pathways in various disease states, miRNA may potentially be a useful tool for gene intervention. Nevertheless, a single miRNA is predicted to be able to bind to several hundreds of different mRNA [105]. Therefore, should a potential miRNA be developed as a therapeutic target, it would need to be targeted to a specific tissue to avoid unwanted effects which may occur in other tissues in the body. Thus, with the emerging knowledge of the role of miRNA in regulating caveolae related genes, modulating the expression of these key miRNAs could be a useful therapeutic tool, as caveolae related genes have been described to play important roles in health and disease.

Conclusion

Caveolae related genes have been shown to play important roles in health and disease. Apart from genetic mutations, growing evidence suggests that epigenetic mechanisms may provide an upstream regulatory switch to control the expression of caveolae related genes hence contributing to disease conditions. Potentially, these two events may occur concurrently or exclusively to promote disease progression. Identification of epigenetic modifications may open new doors in biomarker and therapeutic target development to complement the current options that have been developed for genetic mutations. Much of the current evidence is focused on the changes in CAV1 expression by methylation, acetylation and miRNA and less is known for CAV2 and PTRF. Therefore, further studies are required to investigate whether altering the epigenetic state of these caveolae related genes can affect disease progression and if they can be used as biomarkers for disease identification.

Abbreviations

CAV1: 

Caveolin-1

CAV2: 

Caveolin-2

CAV3: 

Caveolin-3

PTRF: 

Polymerase-1 and transcript release factor

5-AZA: 

5-AZA-2′-deoxycytidine

TSA: 

Trichostatin-A

DNA: 

Deoxyribonucleic acid

RNA: 

Ribonucleic acid

miRNA: 

Micro-ribonucleic acid

CpGi: 

CpG island

HCC: 

Hepatocellular carcinoma

HNCC: 

Head and neck squamous cell carcinoma

RCC: 

Renal cell carcinoma

DHA: 

Docosahexaenoic acid

TGF-β: 

Transforming growth factor beta

ROMK: 

Renal outer medullary potassium

ER: 

Estrogen receptor

HBV: 

Hepatitis B Virus

IBC: 

Inflammatory breast cancer

kb: 

kilo base

mRNA: 

Messenger ribonucleic acid

Declarations

Acknowledgments

We would like to thank the University of Otago for the Doctoral Scholarship awarded to JYL. This work is supported by University of Otago.

Authors’ Affiliations

(1)
Department of Anatomy, Otago School of Medical Sciences, University of Otago

References

  1. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol. 1955;1(5):445–58.PubMed CentralPubMedGoogle Scholar
  2. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007;8(3):185–94.PubMedGoogle Scholar
  3. Parton RG, del Pozo MA. Caveolae as plasma membrane sensors, protectors and organizers. Nat Rev Mol Cell Biol. 2013;14(2):98–112.PubMedGoogle Scholar
  4. Glenney Jr JR. The sequence of human caveolin reveals identity with VIP21, a component of transport vesicles. FEBS Lett. 1992;314(1):45–8.PubMedGoogle Scholar
  5. Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, Lisanti MP. Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci U S A. 1996;93(1):131–5.PubMed CentralPubMedGoogle Scholar
  6. Tang Z, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, et al. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem. 1996;271(4):2255–61.PubMedGoogle Scholar
  7. Hill MM, Bastiani M, Luetterforst R, Kirkham M, Kirkham A, Nixon SJ, et al. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell. 2008;132(1):113–24.PubMed CentralPubMedGoogle Scholar
  8. Mineo C, Ying YS, Chapline C, Jaken S, Anderson RG. Targeting of protein kinase Calpha to caveolae. J Cell Biol. 1998;141(3):601–10.PubMed CentralPubMedGoogle Scholar
  9. McMahon KA, Zajicek H, Li WP, Peyton MJ, Minna JD, Hernandez VJ, et al. SRBC/cavin-3 is a caveolin adapter protein that regulates caveolae function. EMBO J. 2009;28(8):1001–15.PubMed CentralPubMedGoogle Scholar
  10. Bastiani M, Liu L, Hill MM, Jedrychowski MP, Nixon SJ, Lo HP, et al. MURC/Cavin-4 and cavin family members form tissue-specific caveolar complexes. J Cell Biol. 2009;185(7):1259–73.PubMed CentralPubMedGoogle Scholar
  11. Glenney Jr JR, Zokas L. Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol. 1989;108(6):2401–8.PubMedGoogle Scholar
  12. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell. 1992;68(4):673–82.PubMedGoogle Scholar
  13. Le Lay S, Kurzchalia TV. Getting rid of caveolins: phenotypes of caveolin-deficient animals. Biochim Biophys Acta. 2005;1746(3):322–33.PubMedGoogle Scholar
  14. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293(5539):2449–52.PubMedGoogle Scholar
  15. Fra AM, Williamson E, Simons K, Parton RG. De novo formation of caveolae in lymphocytes by expression of VIP21-caveolin. Proc Natl Acad Sci U S A. 1995;92(19):8655–9.PubMed CentralPubMedGoogle Scholar
  16. Cao G, Yang G, Timme TL, Saika T, Truong LD, Satoh T, et al. Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol. 2003;162(4):1241–8.PubMed CentralPubMedGoogle Scholar
  17. Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE, et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol. 2003;285(1):C222–35.PubMedGoogle Scholar
  18. Hassan GS, Jasmin JF, Schubert W, Frank PG, Lisanti MP. Caveolin-1 deficiency stimulates neointima formation during vascular injury. Biochemistry. 2004;43(26):8312–21.PubMedGoogle Scholar
  19. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev. 2004;84(4):1341–79.PubMedGoogle Scholar
  20. Li S, Galbiati F, Volonte D, Sargiacomo M, Engelman JA, Das K, et al. Mutational analysis of caveolin-induced vesicle formation. Expression of caveolin-1 recruits caveolin-2 to caveolae membranes. FEBS Lett. 1998;434(1–2):127–34.PubMedGoogle Scholar
  21. Razani B, Wang XB, Engelman JA, Battista M, Lagaud G, Zhang XL, et al. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Cell Biol. 2002;22(7):2329–44.PubMed CentralPubMedGoogle Scholar
  22. Das K, Lewis RY, Scherer PE, Lisanti MP. The membrane-spanning domains of caveolins-1 and −2 mediate the formation of caveolin hetero-oligomers. Implications for the assembly of caveolae membranes in vivo. J Biol Chem. 1999;274(26):18721–8.PubMedGoogle Scholar
  23. Rybin VO, Grabham PW, Elouardighi H, Steinberg SF. Caveolae-associated proteins in cardiomyocytes: caveolin-2 expression and interactions with caveolin-3. Am J Physiol Heart Circ Physiol. 2003;285(1):H325–32.PubMedGoogle Scholar
  24. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M, et al. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem. 1996;271(25):15160–5.PubMedGoogle Scholar
  25. Capozza F, Cohen AW, Cheung MW, Sotgia F, Schubert W, Battista M, et al. Muscle-specific interaction of caveolin isoforms: differential complex formation between caveolins in fibroblastic vs. muscle cells. Am J Physiol Cell Physiol. 2005;288(3):C677–91.PubMedGoogle Scholar
  26. Capozza F, Combs TP, Cohen AW, Cho YR, Park SY, Schubert W, et al. Caveolin-3 knockout mice show increased adiposity and whole body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle. Am J Physiol Cell Physiol. 2005;288(6):C1317–31.PubMedGoogle Scholar
  27. Galbiati F, Engelman JA, Volonte D, Zhang XL, Minetti C, Li M, et al. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J Biol Chem. 2001;276(24):21425–33.PubMedGoogle Scholar
  28. Park DS, Woodman SE, Schubert W, Cohen AW, Frank PG, Chandra M, et al. Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. Am J Pathol. 2002;160(6):2207–17.PubMed CentralPubMedGoogle Scholar
  29. Jansa P, Mason SW, Hoffmann-Rohrer U, Grummt I. Cloning and functional characterization of PTRF, a novel protein which induces dissociation of paused ternary transcription complexes. EMBO J. 1998;17(10):2855–64.PubMed CentralPubMedGoogle Scholar
  30. Jansa P, Grummt I. Mechanism of transcription termination: PTRF interacts with the largest subunit of RNA polymerase I and dissociates paused transcription complexes from yeast and mouse. Mol Gen Genet. 1999;262(3):508–14.PubMedGoogle Scholar
  31. Wanaski SP, Ng BK, Glaser M. Caveolin scaffolding region and the membrane binding region of SRC form lateral membrane domains. Biochemistry. 2003;42(1):42–56.PubMedGoogle Scholar
  32. Rajab A, Straub V, McCann LJ, Seelow D, Varon R, Barresi R, et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet. 2010;6(3):e1000874.PubMed CentralPubMedGoogle Scholar
  33. Gould ML, Williams G, Nicholson HD. Changes in caveolae, caveolin, and polymerase 1 and transcript release factor (PTRF) expression in prostate cancer progression. Prostate. 2010;70(15):1609–21.PubMedGoogle Scholar
  34. Liu L, Brown D, McKee M, Lebrasseur NK, Yang D, Albrecht KH, et al. Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. Cell Metab. 2008;8(4):310–7.PubMed CentralPubMedGoogle Scholar
  35. Liu L, Pilch PF. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J Biol Chem. 2008;283(7):4314–22.PubMedGoogle Scholar
  36. Govender P, Romero F, Shah D, Paez J, Ding SY, Liu L, et al. Cavin1; a regulator of lung function and macrophage phenotype. PLoS One. 2013;8(4):e62045.PubMed CentralPubMedGoogle Scholar
  37. Sward K, Sadegh MK, Mori M, Erjefalt JS, Rippe C. Elevated pulmonary arterial pressure and altered expression of Ddah1 and Arg1 in mice lacking cavin-1/PTRF. Physiol Rep. 2013;1(1):e00008.PubMed CentralPubMedGoogle Scholar
  38. Sward K, Albinsson S, Rippe C. Arterial dysfunction but maintained systemic blood pressure in cavin-1-deficient mice. PLoS One. 2014;9(3):e92428.PubMed CentralPubMedGoogle Scholar
  39. Low JY, Nicholson HD. Emerging role of polymerase-1 and transcript release factor (PTRF/ Cavin-1) in health and disease. Cell Tissue Res. 2014;357(3):505–13.PubMedGoogle Scholar
  40. Hansen CG, Bright NA, Howard G, Nichols BJ. SDPR induces membrane curvature and functions in the formation of caveolae. Nat Cell Biol. 2009;11(7):807–14.PubMed CentralPubMedGoogle Scholar
  41. Briand N, Dugail I, Le Lay S. Cavin proteins: New players in the caveolae field. Biochimie. 2011;93(1):71–7.PubMedGoogle Scholar
  42. Tagawa M, Ueyama T, Ogata T, Takehara N, Nakajima N, Isodono K, et al. MURC, a muscle-restricted coiled-coil protein, is involved in the regulation of skeletal myogenesis. Am J Physiol Cell Physiol. 2008;295(2):C490–8.PubMedGoogle Scholar
  43. Bai L, Deng X, Li Q, Wang M, An W, Deli A, et al. Down-regulation of the cavin family proteins in breast cancer. J Cell Biochem. 2012;113(1):322–8.PubMedGoogle Scholar
  44. Michel V, Bakovic M. Lipid rafts in health and disease. Biol Cell. 2007;99(3):129–40.PubMedGoogle Scholar
  45. Verma M, Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol. 2002;3(12):755–63.PubMedGoogle Scholar
  46. De Carvalho DD, You JS, Jones PA. DNA methylation and cellular reprogramming. Trends Cell Biol. 2010;20(10):609–17.PubMed CentralPubMedGoogle Scholar
  47. Gowher H, Jeltsch A. Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy. Cancer Biol Ther. 2004;3(11):1062–8.PubMedGoogle Scholar
  48. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123(1):8–13.PubMedGoogle Scholar
  49. Bui C, Ouzzine M, Talhaoui I, Sharp S, Prydz K, Coughtrie MW, et al. Epigenetics: methylation-associated repression of heparan sulfate 3-O-sulfotransferase gene expression contributes to the invasive phenotype of H-EMC-SS chondrosarcoma cells. FASEB J. 2010;24(2):436–50.PubMedGoogle Scholar
  50. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009;41(2):178–86.PubMed CentralPubMedGoogle Scholar
  51. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet. 2009;41(12):1350–3.PubMed CentralPubMedGoogle Scholar
  52. Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A. 1964;51:786–94.PubMed CentralPubMedGoogle Scholar
  53. Ng HH, Bird A. Histone deacetylases: silencers for hire. Trends Biochem Sci. 2000;25(3):121–6.PubMedGoogle Scholar
  54. Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays. 1995;17(5):423–30.PubMedGoogle Scholar
  55. Engelman JA, Zhang XL, Lisanti MP. Sequence and detailed organization of the human caveolin-1 and −2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett. 1999;448(2–3):221–30.PubMedGoogle Scholar
  56. Syeed N, Hussain F, Husain SA, Siddiqi MA. 5′-CpG island promoter hypermethylation of the CAV-1 gene in breast cancer patients of Kashmir. Asian Pac J Cancer Prev. 2012;13(1):371–5.PubMedGoogle Scholar
  57. Chen ST, Lin SY, Yeh KT, Kuo SJ, Chan WL, Chu YP, et al. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers. Int J Mol Med. 2004;14(4):577–82.PubMedGoogle Scholar
  58. Alevizos L, Kataki A, Derventzi A, Gomatos I, Loutraris C, Gloustianou G, et al. Breast cancer nodal metastasis correlates with tumour and lymph node methylation profiles of Caveolin-1 and CXCR4. Clin Exp Metastasis. 2014;31(5):511–20.PubMedGoogle Scholar
  59. Deb M, Sengupta D, Kar S, Rath SK, Parbin S, Shilpi A, et al. Elucidation of caveolin 1 both as a tumor suppressor and metastasis promoter in light of epigenetic modulators. Tumour Biol. 2014;35(12):12031–47.PubMedGoogle Scholar
  60. Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, et al. Overexpression of caveolin-1 and −2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat. 2006;95(3):219–28.PubMedGoogle Scholar
  61. Rao X, Evans J, Chae H, Pilrose J, Kim S, Yan P, et al. CpG island shore methylation regulates caveolin-1 expression in breast cancer. Oncogene. 2013;32(38):4519–28.PubMed CentralPubMedGoogle Scholar
  62. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate. 2001;46(3):249–56.PubMedGoogle Scholar
  63. Yang B, Bhusari S, Kueck J, Weeratunga P, Wagner J, Leverson G, et al. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia. 2013;15(4):399–408.PubMed CentralPubMedGoogle Scholar
  64. Bachmann N, Haeusler J, Luedeke M, Kuefer R, Perner S, Assum G, et al. Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma. Cancer Genet Cytogenet. 2008;182(2):103–10.PubMedGoogle Scholar
  65. Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008;27(4):715–35.PubMedGoogle Scholar
  66. Dennis JW, Pawling J, Cheung P, Partridge E, Demetriou M. UDP-N-acetylglucosamine:alpha-6-D-mannoside beta1,6 N-acetylglucosaminyltransferase V (Mgat5) deficient mice. Biochim Biophys Acta. 2002;1573(3):414–22.PubMedGoogle Scholar
  67. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J. 2004;19(7–9):543–9.PubMedGoogle Scholar
  68. Kunze E, Von Bonin F, Werner C, Wendt M, Schlott T. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. Int J Mol Med. 2006;17(1):3–13.PubMedGoogle Scholar
  69. Kunze E, Schlott T. High frequency of promoter methylation of the 14-3-3 sigma and CAGE-1 genes, but lack of hypermethylation of the caveolin-1 gene, in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder. Int J Mol Med. 2007;20(4):557–63.PubMedGoogle Scholar
  70. Sunaga N, Miyajima K, Suzuki M, Sato M, White MA, Ramirez RD, et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res. 2004;64(12):4277–85.PubMedGoogle Scholar
  71. Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol. 2001;159(5):1635–43.PubMed CentralPubMedGoogle Scholar
  72. Lin SY, Yeh KT, Chen WT, Chen HC, Chen ST, Chang JG. Promoter CpG methylation of caveolin-1 in sporadic colorectal cancer. Anticancer Res. 2004;24(3a):1645–50.PubMedGoogle Scholar
  73. Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology. 2006;131(3):797–808.PubMedGoogle Scholar
  74. Ha TK, Her NG, Lee MG, Ryu BK, Lee JH, Han J, et al. Caveolin-1 increases aerobic glycolysis in colorectal cancers by stimulating HMGA1-mediated GLUT3 transcription. Cancer Res. 2012;72(16):4097–109.PubMedGoogle Scholar
  75. Hirasawa Y, Arai M, Imazeki F, Tada M, Mikata R, Fukai K, et al. Methylation status of genes upregulated by demethylating agent 5-aza-2′-deoxycytidine in hepatocellular carcinoma. Oncology. 2006;71(1–2):77–85.PubMedGoogle Scholar
  76. Dewantoro O, Gani RA, Akbar N. Hepatocarcinogenesis in viral Hepatitis B infection: the role of HBx and p53. Acta Med Indones. 2006;38(3):154–9.PubMedGoogle Scholar
  77. Yan J, Lu Q, Dong J, Li X, Ma K, Cai L. Hepatitis B virus X protein suppresses caveolin-1 expression in hepatocellular carcinoma by regulating DNA methylation. BMC Cancer. 2012;12:353.PubMed CentralPubMedGoogle Scholar
  78. McEwen BS. Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol (1985). 2001;91(6):2785–801.Google Scholar
  79. Behl C. Oestrogen as a neuroprotective hormone. Nat Rev Neurosci. 2002;3(6):433–42.PubMedGoogle Scholar
  80. Zschocke J, Manthey D, Bayatti N, van der Burg B, Goodenough S, Behl C. Estrogen receptor alpha-mediated silencing of caveolin gene expression in neuronal cells. J Biol Chem. 2002;277(41):38772–80.PubMedGoogle Scholar
  81. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37(5):495–500.PubMedGoogle Scholar
  82. Farazi TA, Juranek SA, Tuschl T. The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members. Development. 2008;135(7):1201–14.PubMedGoogle Scholar
  83. Bostjancic E, Jerse M, Glavac D, Zidar N. miR-1, miR-133a/b, and miR-208a in human fetal hearts correlate to the apoptotic and proliferation markers. Exp Biol Med (Maywood). 2014;240(2):211–9.Google Scholar
  84. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006;38(2):228–33.PubMed CentralPubMedGoogle Scholar
  85. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–70.PubMedGoogle Scholar
  86. Nohata N, Hanazawa T, Kikkawa N, Mutallip M, Fujimura L, Yoshino H, et al. Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol. 2011;38(1):209–17.PubMedGoogle Scholar
  87. Lin DH, Yue P, Pan C, Sun P, Wang WH. MicroRNA 802 stimulates ROMK channels by suppressing caveolin-1. J Am Soc Nephrol. 2011;22(6):1087–98.PubMed CentralPubMedGoogle Scholar
  88. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474(7353):649–53.PubMedGoogle Scholar
  89. Nystrom FH, Chen H, Cong LN, Li Y, Quon MJ. Caveolin-1 interacts with the insulin receptor and can differentially modulate insulin signaling in transfected Cos-7 cells and rat adipose cells. Mol Endocrinol. 1999;13(12):2013–24.PubMedGoogle Scholar
  90. Lino Cardenas CL, Henaoui IS, Courcot E, Roderburg C, Cauffiez C, Aubert S, et al. miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1. PLoS Genet. 2013;9(2):e1003291.PubMed CentralPubMedGoogle Scholar
  91. Shi XE, Li YF, Jia L, Ji HL, Song ZY, Cheng J, et al. MicroRNA-199a-5p affects porcine preadipocyte proliferation and differentiation. Int J Mol Sci. 2014;15(5):8526–38.PubMed CentralPubMedGoogle Scholar
  92. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, et al. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem. 2002;277(10):8635–47.PubMedGoogle Scholar
  93. Yang S, Liu X, Li X, Sun S, Sun F, Fan B, et al. MicroRNA-124 reduces caveolar density by targeting caveolin-1 in porcine kidney epithelial PK15 cells. Mol Cell Biochem. 2013;384(1–2):213–9.PubMedGoogle Scholar
  94. Gil-Zamorano J, Martin R, Daimiel L, Richardson K, Giordano E, Nicod N, et al. Docosahexaenoic acid modulates the enterocyte Caco-2 cell expression of microRNAs involved in lipid metabolism. J Nutr. 2014;144(5):575–85.PubMedGoogle Scholar
  95. Shatseva T, Lee DY, Deng Z, Yang BB. MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J Cell Sci. 2011;124(Pt 16):2826–36.PubMedGoogle Scholar
  96. Yamasaki T, Seki N, Yoshino H, Itesako T, Hidaka H, Yamada Y, et al. MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway. J Urol. 2013;190(3):1059–68.PubMedGoogle Scholar
  97. Hoeke L, Sharbati J, Pawar K, Keller A, Einspanier R, Sharbati S. Intestinal Salmonella typhimurium infection leads to miR-29a induced caveolin 2 regulation. PLoS One. 2013;8(6):e67300.PubMed CentralPubMedGoogle Scholar
  98. Inder KL, Ruelcke JE, Petelin L, Moon H, Choi E, Rae J, et al. Cavin-1/PTRF alters prostate cancer cell-derived extracellular vesicle content and internalization to attenuate extracellular vesicle-mediated osteoclastogenesis and osteoblast proliferation. J Extracell Vesicles. 2014;3Google Scholar
  99. Pogribny IP. Epigenetic events in tumorigenesis: putting the pieces together. Exp Oncol. 2010;32(3):132–6.PubMedGoogle Scholar
  100. Hayashi YK, Matsuda C, Ogawa M, Goto K, Tominaga K, Mitsuhashi S, et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest. 2009;119(9):2623–33.PubMed CentralPubMedGoogle Scholar
  101. Kim CA, Delepine M, Boutet E, El Mourabit H, Le Lay S, Meier M, et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab. 2008;93(4):1129–34.PubMedGoogle Scholar
  102. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4(12):988–93.PubMedGoogle Scholar
  103. Tost J. DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker. Mol Biotechnol. 2010;44(1):71–81.PubMedGoogle Scholar
  104. Miyamoto K, Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol. 2005;35(6):293–301.PubMedGoogle Scholar
  105. Nilsen TW. Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet. 2007;23(5):243–9.PubMedGoogle Scholar

Copyright

© Low and Nicholson. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement